Literature DB >> 19618711

Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.

Aaron P Turner1, Rhonda M Williams, Alicia P Sloan, Jodie K Haselkorn.   

Abstract

OBJECTIVE: To evaluate the contribution injection anxiety to disease modifying therapy (DMT) adherence among individuals with multiple sclerosis (MS). Injection anxiety has been associated with medication discontinuation early in the course of treatment, but little is known about the relationship between injection anxiety and sustained DMT adherence over time.
METHOD: Eighty-nine outpatients receiving care at a Veterans Administration MS clinic completed a telephone survey at baseline and monthly telephone follow-up for 6 months.
RESULTS: Participants were established DMT users (M = 3.43 years, SD = 3.29), with relatively high adherence overall (over 80% achieved 80% adherence or greater). Using logistic regression and controlling for demographics, MS disability, type of DMT, and time on DMT, the authors found that baseline injection anxiety predicted lower levels of adherence at 4 months and 6 months, with a similar trend at 2 months.
CONCLUSION: Sustained adherence to DMT remains a challenge for a subset of individuals with MS well beyond the initial period of acclimation. Injection anxiety is an important and promising target of psychological intervention during all periods of medication use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19618711     DOI: 10.1037/a0014460

Source DB:  PubMed          Journal:  Rehabil Psychol        ISSN: 0090-5550


  27 in total

1.  A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

Authors:  Howard Zwibel; Gabriel Pardo; Shelly Smith; Douglas Denney; Merrikay Oleen-Burkey
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

Review 2.  The role of comfort and discomfort in insulin therapy.

Authors:  Ronnie Aronson
Journal:  Diabetes Technol Ther       Date:  2012-04-26       Impact factor: 6.118

3.  Adherence to first-line disease-modifying therapy for multiple sclerosis in kuwait.

Authors:  Raed Alroughani; Anil Thussu
Journal:  Int J MS Care       Date:  2012

4.  Predictors of anxiety in multiple sclerosis.

Authors:  Narineh Hartoonian; Alexandra L Terrill; Meghan L Beier; Aaron P Turner; Melissa A Day; Kevin N Alschuler
Journal:  Rehabil Psychol       Date:  2014-12-15

5.  Letter to the Editor: The Emerging Role of Pharmacists in the Multidisciplinary Care of Patients with Multiple Sclerosis.

Authors:  Jordan Schultz; Cindy Weber; John Kamholz
Journal:  Int J MS Care       Date:  2016 Sep-Oct

Review 6.  Psychological Considerations and Interventions in Inflammatory Bowel Disease Patient Care.

Authors:  Tiffany H Taft; Sarah Ballou; Alyse Bedell; Devin Lincenberg
Journal:  Gastroenterol Clin North Am       Date:  2017-10-03       Impact factor: 3.806

Review 7.  Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder.

Authors:  Aaron P Turner; Kevin N Alschuler; Abbey J Hughes; Meghan Beier; Jodie K Haselkorn; Alicia P Sloan; Dawn M Ehde
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

8.  Initiating oral fingolimod treatment in patients with multiple sclerosis.

Authors:  Barry A Singer
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

9.  Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study.

Authors:  G Anderson; D Meyer; C E Herrman; C Sheppard; R Murray; E J Fox; J Mathena; J Conner; P O Buck
Journal:  J Neurol       Date:  2010-10-16       Impact factor: 4.849

10.  Which symptoms matter? Self-report and observer discrepancies in repressors and high-anxious women with metastatic breast cancer.

Authors:  Janine Giese-Davis; Rie Tamagawa; Maya Yutsis; Suzanne Twirbutt; Karen Piemme; Eric Neri; C Barr Taylor; David Spiegel
Journal:  J Behav Med       Date:  2012-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.